Analysis Artemis Medicare Services Limi (ARTEMISMED)
6/1/2024
Analysis of Artemis Medicare Services Limi (ARTEMISMED)
Artemis Medicare Services Limited (ARTEMISMED) has been showing some fluctuations in its stock price over the past few days. The Relative Strength Index (RSI) values have been hovering around the mid-range, indicating a neutral sentiment in the market. The Moving Average Convergence Divergence (MACD) indicator has been negative, suggesting a bearish trend.The stock price has been moving below the Simple Moving Average (SMA), Exponential Moving Average (EMA), and Weighted Moving Average (WMA) values, indicating a downward trend. However, the stock price has shown some resilience by not dropping significantly below these moving averages.
Overall, the stock of Artemis Medicare Services Limited seems to be consolidating with a slightly bearish bias. Traders and investors may want to closely monitor the RSI, MACD, and moving average indicators for potential trend reversals or continuation signals before making any trading decisions.
Earnings
The company's results for the most recent quarter ending on April 30, 2025, have not been provided yet. The previous results from February 27, 2025, were handled by the Transfer Agent. The results from January 31, 2025, were released after hours. The results from October 31, 2024, were not provided at a specific time. The results from August 1, 2024, showed an earnings per share (EPS) estimate of 1.32.Main Statystic ðŸ§
The data provided includes financials, stock statistics, valuation metrics, stock price summary, and dividends and splits information for a specific company.In terms of financials, the company has a strong operating cash flow and levered free cash flow, with a positive current ratio. The profit margin and operating margin are also healthy, indicating efficient operations. The company's fiscal year ends in September 2023, and it has shown a positive return on assets and return on equity.
Looking at stock statistics, the company has a relatively low short ratio and a significant percentage of shares held by institutions. The stock price has fluctuated between a fifty-two-week low and high, with a positive change over the period.
Valuation metrics show a relatively high PEG ratio and price-to-book ratio, with the company's market capitalization and enterprise value being substantial. The price-to-sales ratio and enterprise-to-EBITDA ratio are also notable.
The stock price summary includes beta, moving averages, and the range of prices over the past year. Dividends and splits information shows the company's dividend history, payout ratio, and dividend yield metrics.
Income statement 💸
These are the revenue figures. Here are the conclusions:1. The company's sales revenue has been increasing steadily over the years, from $274.5 billion in 2020 to $383.3 billion in 2023.
2. Despite the increase in sales, the cost of goods sold has also been rising, indicating a potential need for cost management.
3. The gross profit margin has remained relatively stable over the years, suggesting efficient cost control measures.
4. Earnings before interest and taxes (EBIT) have shown an upward trend, reaching $117.7 billion in 2023 from $69.96 billion in 2020.
5. Net income has also been increasing consistently, from $57.41 billion in 2020 to $96.99 billion in 2023.
6. The company has been able to maintain a healthy EBITDA margin over the years, indicating operational efficiency.
7. Diluted earnings per share (EPS) have shown a slight fluctuation but have generally increased from 2020 to 2023.
8. The company's continuous focus on research and development is evident from the increasing expenditure in this area.
9. Non-operating interest expenses have been managed effectively, with a slight decrease over the years.
10. Overall, the financial performance of the company seems to be on a positive trajectory, with increasing revenues and profits.
Balance Sheet
These are balance sheets. Here are the conclusions:1. The total assets have been increasing over the years, reaching $365,725,000,000 in 2018.
2. Current assets include cash, inventory, and receivables, with a significant portion in cash equivalents and short-term investments.
3. Non-current assets consist mainly of investments and advances, along with machinery, furniture, and equipment.
4. Total liabilities have also been increasing, but at a slower pace compared to assets.
5. Shareholders' equity has shown a positive trend, indicating a healthy financial position.
6. The company has been investing in leases, land, and improvements, reflecting a focus on long-term growth.
7. There is a consistent amount of debt in the company's capital structure, both short-term and long-term.
8. The company has been managing its risks by setting aside provisions for risks and charges.
9. Overall, the financial health of the company seems stable and growing steadily over the years.
Cash Flow 💶
This is the cash flow statement. Here are some conclusions we can draw from the data:1. The company's free cash flow has been fluctuating over the years, with the highest value in 2022 and the lowest in 2020.
2. Operating cash flow has generally been increasing year over year, indicating improved operational efficiency.
3. The company has been consistently paying interest and income taxes, with varying amounts each year.
4. The end cash position has also been fluctuating, reaching its highest value in 2020.
5. Financing activities show significant variations, with large amounts being spent on common stock repurchase and debt issuance.
6. Investing activities also vary, with significant amounts being spent on the sale and purchase of investments.
7. Overall, the company's financial activities seem to be dynamic, with fluctuations in cash flow and investment decisions.
Earnings estimate
Based on the analysts' estimates for future quarterly and annual earnings per share:1. For the current quarter ending on June 30, 2024, the average estimated EPS is $1.23, with a low estimate of $1.18 and a high estimate of $1.26. This shows an improvement compared to the EPS of $1.17 from the same quarter a year ago.
2. For the next quarter ending on September 30, 2024, the average estimated EPS is $1.42, with a low estimate of $1.33 and a high estimate of $1.51. This also indicates growth from the EPS of $1.35 in the same quarter last year.
3. Looking at the estimates for the current fiscal year ending on September 30, 2024, the average estimated EPS is $6.10, ranging from a low estimate of $5.95 to a high estimate of $6.41. This reflects an increase from the EPS of $5.67 for the previous fiscal year.
4. For the next fiscal year ending on September 30, 2025, the average estimated EPS is $6.69, with a low estimate of $5.92 and a high estimate of $7.31. This suggests a slight improvement from the EPS of $6.10 in the current fiscal year.
Overall, the analysts' estimates point towards a positive trend of increasing earnings per share for the company in both the short term and the long term.
Revenue estimate
Based on the analysts' estimates for the future quarterly and annual sales of the company, we can draw the following conclusions:1. For the current quarter ending on June 30, 2024, the average sales estimate is $77,545,400,000, with a sales growth of 2% compared to the same quarter last year. The number of analysts providing estimates is 25.
2. For the next quarter ending on September 30, 2024, the average sales estimate is $85,501,800,000, showing a sales growth of 3% compared to the previous year's same quarter. The number of analysts providing estimates is 25.
3. For the current fiscal year ending on September 30, 2024, the average sales estimate is $357,772,000,000, with a sales growth of 1% compared to the previous fiscal year. The number of analysts providing estimates is 38.
4. For the next fiscal year ending on September 30, 2025, the average sales estimate is $380,772,000,000, showing a significant sales growth of 6% compared to the current fiscal year. The number of analysts providing estimates is 38.
Overall, the analysts are forecasting moderate to healthy sales growth for both the upcoming quarters and the next fiscal year, indicating positive expectations for the company's performance in the near future.
Growth estimates
Based on the consensus estimates provided by analysts, we can draw the following conclusions regarding the growth rate of the company for different periods:1. Current Quarter: The estimated growth rate for the current quarter is 5.1%.
2. Next Quarter: The estimated growth rate for the next quarter is 5.2%.
3. Current Year: The estimated growth rate for the current year is 7.6%.
4. Next Year: The estimated growth rate for the next year is 9.7%.
5. Past 5 Years (per annum): The average annual growth rate for the past 5 years is 20.1%.
6. Next 5 Years (per annum): The estimated average annual growth rate for the next 5 years is 9.7%.
These estimates suggest that the company has been experiencing strong growth in the past, and analysts expect this growth to continue at a slightly lower but still healthy rate in the coming years.
Price target
The analysts' forecast for the future price of the security is as follows:- Low: $164
- High: $250
- Median: $200
- Average: $202.26
- Current price: $191.57
Based on these forecasts, it can be observed that the analysts have a relatively wide range of predictions, with the average price being slightly higher than the current price. The median price of $200 indicates that half of the analysts expect the price to be higher than that, while the other half expects it to be lower.
MACD of ARTEMISMED
This is not investment advice. Remember to verify the information provided here.
Get access to the full analysis
- Over 35 000 indexes
- CFD, Forex, Crypto and Stocks Exchange
- Over 150 Indicators
- Pattern and candle analysis
- Support and resistance levels
- Fundamental, technical and sentimental analysis
- Power from AI
